Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

BACKGROUND: Diabetes mellitus is an important risk factor for atrial fibrillation (AF) development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the treatment of type 2 diabetes mellitus (T2DM). Their cardioprotective effects have been reported but whether they prevent AF in T2DM...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Qingmiao, Meng, Lei, Lee, Sharen, Tse, Gary, Gong, Mengqi, Zhang, Zhiwei, Zhao, Jichao, Zhao, Yungang, Li, Guangping, Liu, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882319/
https://www.ncbi.nlm.nih.gov/pubmed/31779619
http://dx.doi.org/10.1186/s12933-019-0964-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882319/
https://www.ncbi.nlm.nih.gov/pubmed/31779619
http://dx.doi.org/10.1186/s12933-019-0964-4

Ejemplares similares